◼ Archived
Business
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
1 trends tracked about this subject — the full history, oldest to newest below.
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.